Fluorouracil is indicated alone or in combination for:
Fluorouracil is inactive as such in mammalian cells but is converted into the active 5-fluorodeoxyuridine monophosphate (FdUMP) by a variety of different metabolic pathways. The drug works by inhibiting the enzyme thymidylate kinase, which results in reduced formation of thymidine and thus of DNA. The active metabolite FdUMP appears to form a stable complex with the folate cofactor N-5,10-methylene tetrahydrofolate, which inactivates thymidylate kinase. Fluorouracil as FdUMP is also incorporated into RNA, which results in fluorination of RNA. The effect of fluorouracil on living cells is limited mainly to those in the proliferative phase, but while cells in the G₂ and S phase are most affected, there may be effects at any stage of the cell cycle.
Intravenous 5-fluorouracil can be delivered by rapid intravenous bolus injection or slow infusion. The vial contents can be rapidly injected directly into a peripheral vein, the most common schedules being 12-13.5 mg/kg (500 mg/m²) daily for 5 days repeated at 4-weekly intervals. Slow intravenous infusion requires the drug to be diluted in 500 ml of 5% dextrose solution, then infused over 2-3 hours on 5 successive days.
For palliative management of cancer: Initial Dose: 12 mg/kg intravenously once daily for 4 successive days. Maximum Dose: 800 mg/day. If no toxicity is observed, 6 mg/kg may be administered on the 6th, 8th, 10th, and 12th day (no therapy is given on days 5, 7, 9, or 11). Discontinue at the end of day 12, even with no apparent toxicity.
Poor risk patients and those who are not in an adequate nutritional state: Initial Dose: 6 mg/kg/day for 3 days. Maximum Dose: 400 mg/day. If no toxicity is observed, 3 mg/kg may be administered on days 5, 7, and 9 (no therapy is to be administered on days 4, 6, or 8). Discontinue at the end of day 9, even with no apparent toxicity.
Maintenance therapy: In instances where toxicity has not been a problem, it is recommended that therapy be continued using either of the following schedules:
Repeat the dosage of the first course every 30 days after the last day of the previous course, or
When the toxic signs resulting from the initial course of therapy have subsided, administer a maintenance dose of 10 to 15 mg/kg/week as a single dose. Maximum Dose: 1 g/week. The reaction of the patient to the previous course of therapy should be taken into account and the dosage should be adjusted accordingly.
Usual adult dose for cervical cancer: In combination with cisplatin, 1 g/m² IV on day 1. The cycle is repeated every 21 days.
Usual pediatric dose for malignant disease: The manufacturer has reported that the safety and effectiveness of fluorouracil have not been established in children. However, the drug has been used in children following adult guidelines.
Intra-arterial infusion: Fluorouracil has also been given by intra-arterial infusion for adults in doses of 5 to 7.5 mg/kg body weight dissolved in 20-100 ml of 5% dextrose solution and administered for 10-20 days using an infusion pump.
Combination with radiation: The usual adult daily dose of 5-10 mg/kg body weight is given in combination with radiation according to the systemic administration method or intra-arterial infusion method.
Combination with other anticancer drugs: Fluorouracil is used alone or in combination in the adjuvant treatment of breast and gastrointestinal cancer, and palliation of inoperable malignant neoplasms, especially those of the gastrointestinal tract, breast, head and neck, liver, genitourinary system, and pancreas. It is also used with cyclophosphamide and methotrexate in the combination chemotherapy of breast cancer. A usual adult dose of 5 to 10 mg/kg body weight daily is given in combination with other anticancer drugs every day or intermittently once to twice a week by the systemic administration method or intra-arterial infusion method.
Pre-treatment with cimetidine for 4 weeks led to increased plasma concentrations of fluorouracil following intravenous and oral administration in 6 patients. The effect was probably due to a combination of hepatic enzyme inhibition and reduced hepatic blood flow.
It is contraindicated in patients that are severely debilitated or in patients with bone marrow suppression due to either radiotherapy or chemotherapy. It is likewise contraindicated in pregnant or breastfeeding women. It should also be avoided in patients that do not have malignant illnesses.
Potentially life-threatening effects: Severe effects from 5-fluorouracil are related to the dosage and duration of therapy.
Cardiac effects: Occasional case reports associating 5-fluorouracil therapy with ischemic cardiac events. Evidence against the autoimmune phenomenon is the fact that in several cases cardiotoxicity occurred within several hours of the first dose.
Hematological effects: Potentially lethal effects caused by severe hematological toxicity may develop within the first 10 days of treatment being instituted but generally resolve within 3 weeks. At the recommended dose and schedule, it is rather uncommon for hematological toxicity to be severe. Anything that contributes to severe effects from 5-fluorouracil on the blood-forming cells, such as extensive prior irradiation or the concomitant use of cytotoxic drugs, tends to exacerbate the severity of the hematological side effects of 5-fluorouracil.
Neurological effects: Effects on the central nervous system have been occasionally reported, and cerebral ataxia is dose-dependent with an incidence of between 3.1 and 7%. Acute cerebellar syndromes and myelopathy have been described following intrathecal 5-fluorouracil. Neurological syndromes may occur rarely after carotid artery perfusion in head and neck cancer.
Other effects: Allergic reaction (including difficulty in breathing, closing of the throat, swelling of the lips, tongue, or face, or hives), decreased bone marrow function and blood problems (extreme fatigue, easy bruising or bleeding, black, bloody or tarry stools, or fever, chills, or signs of infection), hand-foot syndrome (tingling, pain, redness, swelling or tenderness of the hands and feet), severe vomiting, diarrhoea, frequent bowel movements or watery stools, or sores in the mouth or throat, or stomach pain or heartburn or black, bloody or tarry stools. Other less serious side effects may include mild to moderate nausea, vomiting or loss of appetite, balance problems, confusion, rash and itching, or temporary hair loss. Conjunctivitis, both acute and chronic, can proceed to tear duct stenosis and ectropion following prolonged administration. Very chronic administration, extending beyond 3 months, of low dosage has been associated with low systemic toxicity but includes the possibility of painful and tender hands and feet associated with erythema of the extremities.
Fluorouracil is contraindicated throughout pregnancy. The literature pertaining to pregnancy and cytotoxic drugs is necessarily limited, but it appears in general that the risk of teratogenesis diminishes with the advancement of pregnancy. Therefore, most cytotoxic drugs are absolutely contraindicated in the first trimester, and 5-fluorouracil used in the first trimester has been reported to cause multiple congenital abnormalities. There are many case reports, however, of pregnancy being conducted successfully with combination chemotherapy being given to the mother during the second and third trimesters. Because of the age of the population and the natural history of the tumors treated, most of the data on long-term follow-up pertain to therapy for leukemias. More data need to be accrued on the subsequent development of neonates before it is certain that any of these compounds are free of late effects.
It is not known whether fluorouracil is excreted in human milk. Because fluorouracil inhibits DNA, RNA and protein synthesis, mothers should not nurse while receiving this drug.
5-fluorouracil is a highly toxic drug with a narrow margin of safety. Therefore, patients should be carefully supervised, since therapeutic response is unlikely to occur without some evidence of toxicity. The daily dose should not exceed 1 gram. Treatment should be discontinued promptly when one of the following signs of toxicity appears: leucopenia (WBC under 3500/mm³), thrombocytopenia (platelet under 100,000/mm³), stomatitis (the first small ulceration at the inner margin of the lips is a signal for stopping treatment), severe diarrhoea (frequent bowel movements and watery stools), or gastrointestinal ulceration and bleeding.
Neonates: No dosage recommendations are made for neonates.
Children: Safety and effectiveness in children have not been established.
The elderly: No special precautions are required, doses being adjusted for the patient's weight and height.
Cases of deliberate overdose are unknown, but excessive toxicity occurs because of the hematological effects as described above. There is no specific antidote to 5-fluorouracil toxicity; treatment consists of supportive care. In addition to hematological toxicity, other toxicities will occur with overdose. Signs and symptoms are qualitatively similar to the side effects. Treatment should be performed promptly, and appropriate drugs are given to control symptoms of overdose.
Store the vial in the original carton not exceeding 25°C. Do not refrigerate. Protect from light.
What is Fluorouracil used for?
What does Fluorouracil do?
What are the side effects of Fluorouracil?
What happens if you take too much Fluorouracil?
Can Fluorouracil be taken during pregnancy?
No available drugs found